IBI-129
- Generic Name
- IBI-129
A Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05991349
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Wollongong Hospital, Wollongong, New South Wales, Australia
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath